Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-ENDO + Docetaxel in advanced solid tumors
NCT04413227Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Apr 2020
- Primary completion
- May 2021
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegylated recombinant human endostatin in non-small cell lung cancer (NSCLC) and solid tumor (5 cohorts), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Event and 8 more. Status: unknown.
02
Drugs
pegylated recombinant human endostatin
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04413227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04413227.